| Literature DB >> 35407477 |
Yi-Jun Liao1, Wan-Tzu Lin1, Hsin-Ju Tsai1, Chia-Chang Chen1, Chun-Fang Tung1, Sheng-Shun Yang1,2,3,4, Yen-Chun Peng1,5,6.
Abstract
Severe acute cholangitis is a life-threatening medical emergency. Endoscopic biliary drainage (EBD) or percutaneous transhepatic biliary drainage (PTBD) is usually used for biliary decompression. However, it can be risky to transport a critical patient to the radiology unit. We aimed to compare clinical outcomes between bedside, radiation-free EBD and fluoroscopic-guided PTBD in patients under critical care.Entities:
Keywords: acute cholangitis; critically ill; endoscopic biliary drainage; percutaneous biliary drainage
Year: 2022 PMID: 35407477 PMCID: PMC8999535 DOI: 10.3390/jcm11071869
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241
Figure 1Flowchart of patients enrolled in this study. ICU, intensive care unit.
Baseline characteristics of study subjects.
| Characteristics | EBD ( | PTBD ( | |
|---|---|---|---|
| Age, median (range), years | 81.60 (68.93–86.12) | 78.22 (68.76–84.76) | 0.74 |
| Gender, Male (%) | 9 (50.00) | 15 (48.39) | 1.00 |
| APACHE II score, median (range) | 28 (24.5–34.25) | 27 (21–33) | 0.47 |
| Underling comorbidities, | |||
| Hypertension | 6 (37.50) | 19 (61.29) | 0.22 |
| Type 2 diabetes mellitus | 5 (31.25) | 12 (38.71) | 0.85 |
| Chronic kidney disease | 7 (43.75) | 11 (35.48) | 0.81 |
| Congestive heart failure | 6 (37.50) | 5 (16.13) | 0.15 |
| Liver cirrhosis | 2 (12.50) | 4 (12.90) | 1.00 |
| Cerebral vascular accident | 3 (18.75) | 3 (9.68) | 0.40 |
| COPD | 4 (25.00) | 4 (12.90) | 0.42 |
| Pancreaticobiliary malignancy | 1 (6.25) | 4 (12.90) | 0.65 |
| Other malignancy | 5 (31.25) | 3 (9.68) | 0.10 |
| APACHE II score, median (range) | 26.5 (23.5–33.75) | 27 (21–33) | 0.71 |
| Septic shock, | 12 (75.00) | 24 (77.42) | 1.00 |
| Bacteremia, | 5 (31.25) | 16 (51.61) | 0.31 |
| Acute renal failure, | 8 (50.00) | 20 (64.52) | 0.52 |
| Emergent hemodialysis, | 5 (31.25) | 12 (38.71) | 0.85 |
| PTINR > 1.5, | 5 (31.25) | 5 (16.13) | 0.41 |
| Platelet < 100,000/mm3, | 9 (56.25) | 14 (45.16) | 0.68 |
| Time to biliary drainage (day) | 3.5 (2–6.75) | 1 (1–3) | 0.01 * |
* p < 0.05. Continuous data are presented as median (IQR, 25th–75th percentile). Categorical data are presented as numbers and percentages. EBD: endoscopic biliary drainage; PTBD: percutaneous transhepatic biliary drainage; COPD, chronic obstructive pulmonary disease; APACHE II, Acute Physiology and Chronic Health Evaluation II; PTINR, prothrombin time of an international normalized ratio.
Clinical data before and after biliary drainage.
| EBD ( | PTBD ( | ||
|---|---|---|---|
| Pre-drainage | |||
| WBC (×1000/μL) | 11.73 (7.51–17.53) | 16.85 (9.34–21) | 0.08 |
| Hemoglobin (g/dL) | 9.05 (8.05–11.03) | 10.5 (9.4–12.1) | 0.03 |
| Platelet (×1000/μL) | 90 (43.25–154.50) | 117 (67–196) | 0.21 |
| Total bilirubin (mg/dL) | 5.45 (3.00–11.25) | 4.8 (2.4–8.3) | 0.45 |
| Alk-P (U/L) | 234 (121.75–416.50) | 317 (166–506) | 0.24 |
| AST (U/L) | 94 (57–188.5) | 113 (65–239) | 0.44 |
| ALT(U/L) | 36 (18.5–97.5) | 88 (41–153) | 0.03 * |
| PTINR | 1.25 (1.15–1.65) | 1.26 (1.17–1.36) | 0.77 |
| Creatinine (mg/dL) | 2.02 (0.81–3.59) | 1.69 (1.12–3.04) | 0.74 |
| Post-drainage | |||
| WBC (×1000/μL) | 10.05 (9.28–12.7) | 15.73 (11.2–21.29) | 0.05 |
| Hemoglobin(g/dL) | 9.35 (7.95–10.23) | 9.8 (8.9–10.9) | 0.20 |
| Platelet (×1000/μL) | 79.5 (47–143.25) | 74 (49–124) | 0.88 |
| Total bilirubin (mg/dL) | 5 (2.3–14.2) | 4.1 (1.2–6.6) | 0.31 |
| ΔTotal bilirubin | 0.2 (−1–2.73) | 0.7 (−2–2.2) | 0.75 |
| Alk-P (U/L) | 209 (143–540.75) | 207 (131–382) | 0.73 |
| AST (U/L) | 66 (41–184) | 98.5 (40.75–194) | 0.71 |
| ALT (U/L) | 20 (15–63) | 74 (33–148.75) | 0.02 * |
| PTINR | 1.57 (1.16–1.81) | 1.15 (1.05–1.38) | 0.02 * |
| Creatinine (mg/dL) | 1.42 (90.85–2.93) | 2.06 (0.86–2.70) | 0.65 |
* p < 0.05. Continuous data are presented as median (IQR, 25th–75th percentile). EBD: endoscopic biliary drainage; PTBD: percutaneous transhepatic biliary drainage; WBC, white blood count; AlK-P, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PTINR, prothrombin time international normalized ratio; ΔTotal bilirubin, pre-drainage total bilirubin minus post drainage total bilirubin.
ERCP indications, procedures and outcome in 16 patients.
| EBD ( | |
|---|---|
| Indications, | |
| CBD dilatation, cholangitis | 5 (31.25) |
| Choledocholithiasis | 8 (50.00) |
| Biliary pancreatitis | 1 (6.25) |
| Post-operation biliary leakage | 1 (6.25) |
| Ampulla vater tumor | 1 (6.25) |
| Procedure time (min), median (IQR) | 20 (20.35) |
| Interventions, | |
| EPT | 1 (6.25) |
| ERBD | 15 (93.75) |
| Technical success, | 15 (93.75) |
| Adverse events, | 1 (6.25) |
| Overall 30-day mortality rate | 5 (31.25) |
EBD: endoscopic biliary drainage; EPT, endoscopic papillotomy; ERBD, endoscopic Retrograde Biliary Drainage.
Figure 2The overall 30-day mortality rate of the two groups. EBD: endoscopic biliary drainage; PTBD: percutaneous transhepatic biliary drainage.
Predictive factors associated with 30-day mortality.
| Variable | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Group (PTBD vs. EBD) | 0.97 | (0.33–2.84) | 0.956 | |||
| Age | 1.05 | (0.99–1.12) | 0.082 | |||
| Male gender | 0.99 | (0.36–2.73) | 0.982 | |||
| APACHE II score | 1.05 | (0.97–1.14) | 0.195 | |||
| Underlying comorbidities | ||||||
| Chronic kidney disease | 1.44 | (0.52–3.98) | 0.480 | |||
| Congestive heart failure | 1.84 | (0.63–5.40) | 0.264 | |||
| Liver cirrhosis | 2.28 | (0.64–8.13) | 0.202 | |||
| COPD | 0.78 | (0.18–3.47) | 0.747 | |||
| Pancreaticobiliary malignancy | 0.56 | (0.07–4.28) | 0.578 | |||
| Other malignancy | 3.73 | (1.27–11.01) | 0.017 * | 5.27 | (1.01–27.57) | 0.049 * |
| Septic shock | 0.54 | (0.18–1.58) | 0.262 | |||
| Time to drainage >2 days | 2.68 | (0.95–7.57) | 0.062 | |||
| Emergent dialysis | 4.86 | (1.65–14.29) | 0.004 * | 7.30 | (2.20–24.24) | 0.001 ** |
| Pre-drainage data | ||||||
| WBC (×1000/μL) | 1.00 | (1.00–1.00) | 0.339 | |||
| Hemoglobin (g/dL) | 0.92 | (0.74–1.15) | 0.451 | |||
| Platelet (×1000/μL) | 1.00 | (0.99–1.01) | 0.716 | |||
| Total bilirubin (mg/dL) | 0.27 | (0.97–1.13) | 0.273 | |||
| AlK-P (U/L) | 1.00 | (1.00–1.00) | 0.752 | |||
| AST (U/L) | 1.00 | (1.00–1.00) | 0.173 | |||
| ALT (U/L) | 1.00 | (1.00–1.00) | 0.902 | |||
| PTINR | 4.14 | (1.18–14.57) | 0.027 * | 3.42 | (0.68–17.32) | 0.137 |
| ΔTotal bilirubin | 0.82 | (0.73–0.93) | 0.001 ** | 0.90 | (0.76–1.06) | 0.197 |
* p < 0.05, ** p < 0.01. PTBD, percutaneous transhepatic biliary drainage; EBD, endoscopic biliary drainage; COPD, chronic obstructive pulmonary disease; WBC, white blood count; AlK-P, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PTINR, prothrombin time international normalized ratio; ΔTotal bilirubin, pre-drainage total bilirubin minus post-drainage total bilirubin; HR, hazard ratio; CI, confidence interval.